Berkeley Lights to Participate at the 27th European Society for Animal Cell Technology Meeting
June 22 2022 - 8:35AM
Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell
biology, today announced its participation at the 27th Annual
European Society for Animal Cell Technology (ESCAT), being held
from June 26 - 29, 2022 at the Lisbon Congress Centre in Lisbon,
Portugal. This year’s conference, with the motto, “Advanced Cell
Technologies: Making Protein, Cell, and Gene Therapies a Reality,”
is designed to provide scientists, engineers and other specialists
access to the latest innovations, advances, tools and equipment in
cell technology.
At ESCAT, Berkeley Lights will participate in a symposium
session focused on accelerating cell line engineering and
development. The company will also feature its Beacon platform
technology and workflows in booth #39 for attendees to explore with
hands-on demonstrations of our Optofluidic technology as well as
how to apply the Berkeley Lights Custom Productivity Assay to
rapidly select clones that are producing high-quality bispecific
molecules.
Symposium session: Advance and automate
cell profiling with Berkeley Lights technology and tools to
accelerate cell line engineering and developmentDate:
Sunday, June 26, 10:30 a.m. -12:00 p.m. (GMT+1), Auditorium
VIII
Abstract: Generation of stable CHO cell lines for biologics
manufacturing is a resource-intensive process that can add months
to therapeutic or reagent development timelines. In this ESCAT
symposium session, participants will learn how the Beacon Platform
is removing critical bottlenecks and providing valuable information
on function and quality much earlier in the process by featuring
the work of Rennos Fragkoudis, manager of the Edinburgh Genome
Foundry (EGF) at The University of Edinburgh.
Fragkoudis will present how the EGF’s suite of cutting-edge
computational tools and integrated automation technologies have
facilitated projects in gene therapy, vaccine development and
metabolic engineering. As the first-of-its-kind in a European
academic facility, EGF’s investment in the Beacon Platform has
provided their customers unparalleled access to state-of-the-art
technology to perform previously unworkable high-throughput
single-cell screening experiments.
In addition, Peter O’Callaghan, Head of Expression System
Sciences at Lonza, will present information on how Lonza is
leveraging new cell and process technologies for enhancing cell
line constructions, enabled through the use of its multiple Beacon
Platforms.
Finally, a panel discussion, moderated by Berkeley Lights, will
conclude this symposium session that will focus on the role of
advanced screening technologies, automation, and computational
tools in accelerating cell line engineering and development
projects across academia and industry.
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company
focused on enabling and accelerating the rapid development and
commercialization of biotherapeutics and other cell-based products
for our customers. The Berkeley Lights Platform captures deep
phenotypic, functional, and genotypic information for thousands of
single cells in parallel and can also deliver the live biology
customers desire in the form of the best cells. Our platform is a
fully integrated, end-to-end solution, comprising proprietary
consumables, including our OptoSelect® chips and reagent kits,
advanced automation systems, and application software. We developed
the Berkeley Lights Platform to provide the most advanced
environment for rapid functional characterization of single cells
at scale, the goal of which is to establish an industry standard
for our customers throughout their cell-based product value
chain.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Berkeley Lights
or its products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
Berkeley Lights undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company’s growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
Media
Contact Media@berkeleylights.com
Investor Contact IR@berkeleylights.com
Berkeley Lights (NASDAQ:BLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Berkeley Lights (NASDAQ:BLI)
Historical Stock Chart
From Apr 2023 to Apr 2024